Evidence map›Paper›PMID 39400317›Full record

ArticleInternational journal of cancer2025

Cytokine-armed vaccinia virus promotes cytotoxicity toward pancreatic carcinoma cells via activation of human intermediary CD56

Ruonan Wang, Mengwen Hu, Isis Lozzi, Cao Zhong Jing Jin, Dou Ma, Katrin Splith, Jörg Mengwasser, Vincent Wolf, Linda Feldbrügge, Peter Tang and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ruonan WangDepartment of Surgery, CCM, CVK, Experimental Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Mengwen HuDepartment of Surgery, CCM, CVK, Experimental Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Isis LozziDepartment of Surgery, CCM, CVK, Experimental Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Cao Zhong Jing JinDepartment of Surgery, CCM, CVK, Experimental Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Dou MaDepartment of Surgery, CCM, CVK, Experimental Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Katrin SplithDepartment of General, Visceral and Transplant Surgery, Medizinische Hochschule Hannover, Hannover, Germany.
Jörg MengwasserDepartment of General, Visceral and Transplant Surgery, Medizinische Hochschule Hannover, Hannover, Germany.
Vincent WolfDepartment of General, Visceral and Transplant Surgery, Medizinische Hochschule Hannover, Hannover, Germany.
Linda FeldbrüggeDepartment of General, Visceral and Transplant Surgery, Medizinische Hochschule Hannover, Hannover, Germany.
Peter TangDepartment of Surgery, CCM, CVK, Experimental Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Lea TimmermannDepartment of Surgery, CCM, CVK, Experimental Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Karl Herbert HillebrandtDepartment of Surgery, CCM, CVK, Experimental Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Marieluise KirchnerCore Unit Proteomics, Berlin Institute of Health at Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
Philipp MertinsCore Unit Proteomics, Berlin Institute of Health at Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
Georg HilfenhausBerlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany.
Christopher Claudius Maximilian NeumannBerlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany.
Thomas KammertoensInstitute of Immunology, Charité Unversitätsmedizin, Campus Buch, Berlin, Germany.
Johann PratschkeDepartment of Surgery, CCM, CVK, Experimental Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Thomas MalinkaDepartment of Surgery, CCM, CVK, Experimental Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Igor Maximillian SauerDepartment of Surgery, CCM, CVK, Experimental Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Elfriede NoessnerImmunoanalytics, Helmholtz Zentrum München, Munich, Germany.
Zong Sheng GuoDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Matthäus FelsensteinDepartment of Surgery, CCM, CVK, Experimental Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.ORCID 0000-0003-3146-8717

Funding

China Scholarship Council 201908080257Clinician Scientist - Berlin Institute of Health (BIH)Else Kröner Fresenius Stiftung (EKFS)
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a particularly aggressive disease with few effective treatments. The PDAC tumor immune microenvironment (TIME) is known to be immune suppressive. Oncolytic viruses can increase tumor immunogenicity via immunogenic cell death (ICD). We focused on tumor-selective (vvDD) and cytokine-armed Western-reserve vaccinia viruses (vvDD-IL2 and vvDD-IL15) and infected carcinoma cell lines as well as patient-derived primary PDAC cells. In co-culture experiments, we investigated the cytotoxic response and the activation of human natural killer (NK). Infection and virus replication were assessed by measuring virus encoded YFP. We then analyzed intracellular signaling processes and oncolysis via in-depth proteomic analysis, immunoblotting and TUNEL assay. Following the co-culture of mock or virus infected carcinoma cell lines with allogenic PBMCs or NK cell lines, CD56

Indexed as

CD56 AntigenCoculture TechniquesKiller Cells, NaturalPancreatic NeoplasmsVaccinia virusCarcinoma, Pancreatic DuctalCell Line, TumorCytotoxicity, ImmunologicHumansInterleukin-15Interleukin-2Oncolytic VirotherapyOncolytic VirusesTumor MicroenvironmentCD56 AntigenIL15 protein, humanInterleukin-15Interleukin-2NCAM1 protein, humanimmune modulationimmunogenic cell deathmodified vaccinia virusnatural killer cellsproteome analysis

Identifiers

PMID39400317
PMCPMC11621990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.